Novo-Nordisk A/S


By |


With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Contact Information

Main Phone: +45 44448888
Address: Novo Alle
City / Town: Bagsværd
Country: DNK
Postal Code: 2880

Issuer Information

Exchange: OTO
CEO: Lars Fruergaard Jorgensen
Employees: 43161
NAICS: Pharmaceutical P
$ 46.51 $ 1.33 (2.94%)
Last Price 46.51 Change $ 1.33 Change % 2.94 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open 46.51 High 46.51 Low 46.51 Prev Close 45.18
Last Trade Volume 266,667 52 Wk Hi 58.00 52 Wk Low 40.99
Market Cap 111.4 bi Ex-Div Date Div Rate 0.46 Yield 0.9890
Shares 2,396,043,352.00 EPS (TTM) 2.56 PE Ratio 17.70 Exchange OTCPK